First Tracks Biotherapeutics, Inc.
TRAXNasdaq
$36.52
↑ +0.8%Jul 17 close · end-of-day
Price
1Y↑ +96.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.
- CEO
- Daniel R. Faga
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- www.firsttracksbio.com
Earnings
TRAX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
No annual data.
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$51.3M | -$52.8M |
| Net income | -$47.2M | -$50.5M |
| Diluted EPS | — | — |
| Operating cash flow | -$45.0M | -$32.6M |
| Free cash flow | -$45.0M | -$32.6M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.